Raymond James Financial Services Advisors Inc. Has $698,000 Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Raymond James Financial Services Advisors Inc. grew its holdings in BioNTech SE (NASDAQ:BNTX) by 27.1% during the fourth quarter, Holdings Channel reports. The firm owned 6,611 shares of the company’s stock after acquiring an additional 1,411 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in BioNTech were worth $698,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State of Wyoming acquired a new position in shares of BioNTech in the 2nd quarter valued at about $26,000. Covestor Ltd bought a new stake in BioNTech in the 3rd quarter valued at about $32,000. Eagle Bay Advisors LLC bought a new stake in BioNTech in the 2nd quarter valued at about $33,000. Resurgent Financial Advisors LLC bought a new stake in BioNTech in the 4th quarter valued at about $47,000. Finally, Ramirez Asset Management Inc. bought a new stake in BioNTech in the 3rd quarter valued at about $76,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BNTX has been the subject of a number of research analyst reports. The Goldman Sachs Group decreased their target price on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. JPMorgan Chase & Co. decreased their target price on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research report on Friday, March 22nd. HC Wainwright decreased their target price on BioNTech from $133.00 to $107.00 and set a “buy” rating for the company in a research report on Tuesday, January 23rd. Canaccord Genuity Group reissued a “buy” rating and set a $171.00 price objective on shares of BioNTech in a report on Thursday, March 21st. Finally, BMO Capital Markets decreased their price objective on BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a report on Thursday, March 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $120.40.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $86.34 on Wednesday. BioNTech SE has a twelve month low of $85.21 and a twelve month high of $129.10. The stock’s 50 day moving average price is $91.67 and its 200-day moving average price is $97.64. The company has a market capitalization of $20.53 billion, a PE ratio of 20.96 and a beta of 0.23. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $2.04 billion. On average, equities analysts anticipate that BioNTech SE will post -1.67 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.